Rubius reports $26.4M loss for Q3

PROVIDENCE – Cambridge, Mass.-headquartered Rubius Therapeutics Inc. announced a $26.4 million net loss for the third quarter of 2018 Tuesday. The company reported an $11.9 million loss in the third quarter of 2017. The company, which specializes in allogenic cellular therapies for several diseases and across multiple therapeutic areas, has yet to have a product…
Free Access WeekRegister to read all articles free until July 29! One week only, get full access to all articles on PBN.com when you create a complimentary account. Register Now Already a Subscriber or Registrant? Login now